Evidence map›Paper›PMID 27081720›Full record

ArticleMolecular therapy : the journal of the American Society of Gene Therapy2016

siRNA Therapeutics for Primary Hyperoxaluria: A Beginning.

Dawn S Milliner

Registry-linked trialAbstract readComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02795325 (A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1), which is not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02795325 phase1terminatednot on this map

A Phase 1 Study of DCR-PH1 in Patients With Primary Hyperoxaluria Type 1 (PH1)

TypeinterventionalSponsorDicerna Pharmaceuticals, Inc., a Novo Nordisk companyRan2016 to 2016Enrolled41ConditionsPrimary Hyperoxaluria Type 1ArmsDCR-PH1, Placebo
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Lipid-based nucleic acid therapeutics with in vivo efficacy.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology · 2023
    Review
  2. Recovery From Dialysis in Patients With Primary Hyperoxaluria Type 1 Treated With Pyridoxine: A Report of 3 Cases.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Article
  3. Review
  4. RNA Therapeutics - Research and Clinical Advancements.Frontiers in molecular biosciences · 2021
    Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Dawn S MillinerDivision of Nephrology, Departments of Pediatrics and Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.

Funding

Primary HyperoxaluriaU54DK083908 · NIDDK · MAYO CLINIC ROCHESTER · PI MILLINER, DAWN SCHMAUTZ · 2009 to 2018
$12.3M
NIDDK NIH HHS U54 DK083908
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

RNA, Small InterferingHumansHyperoxaluria, PrimaryKidney Failure, ChronicKidney TransplantationRNA, Small Interfering

Identifiers

PMID27081720
PMCPMC4886951

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.